FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/03/2026
Voltar para busca
Dado oficial do USPTO
S-DUAL
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
06/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
31/01/2023
Data de registro
05/08/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/08/2025
Última transação
06/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
KR
Examinador
BLAZICH, JOAN MICHELE
Unidade examinadora
N40
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Samsung Biologics Co., Ltd.
Representantes
Brian P. Gregg McNees Wallace & Nurick
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Multiple fusion proteins in raw material form for scientific or medical research use; diagnostic reagents for scientific or research use; enzymes for scientific or research purposes; bispecific antibody being monoclonal antibodies for in vitro scientific or medical research use; cell culture reagents for scientific and research use; monoclonal antibodies for in vitro scientific purposes; microorganisms for scientific or laboratory purposesother than for medical and veterinary use; biological preparations for scientific or industrial laboratory purposes; fusion proteins in raw material form for scientific or medical research laboratory purposes; polymerase for nucleic acid for scientific or laboratory purposes; biochemical preparations for scientific purposes; double antibody reagents for scientific purposes; double antibody reagents for scientific purposes in biotechnological product development; biological preparations for use in biotechnologyother than for medical and veterinary use; biochemical catalysts; chemical reagents for use in genetic research for non-medical purposes
Classe 5
Reagents for measurement of HBs antibody for medical purposes; crude medicines for the treatment of cardiovascular diseases; pharmaceutical preparations for activating cellular function; colostral antibodies for veterinary purposes; chemico-pharmaceutical preparations for treating ocular diseases; chemical preparations for use in DNA analysis for medical purposes; bacterial preparations for medical and veterinary use; chemical preparations for medical or veterinary purposesfor bispecific or multispecific antibodies and derivatives thereofto treat cancersinflammatory diseasesautoimmune diseasesinfectious diseases and cardiovascular diseasesneurological disorder and for related diagnostic or therapeutic usefor use in related assays; biotechnological preparations being reagents for medical purposes; biological reagents for medical purposes; biochemical preparations for medical usefor bispecific or multispecific antibodies and derivatives thereofto treat cancersinflammatory diseasesautoimmune diseasesinfectious diseases and cardiovascular diseasesneurological disorder and for related diagnostic or therapeutic usefor use in related assays; reagents for medical use; reagent paper for medical purposes; bispecific colostral antibody for medical purposes; medical diagnostic test strips for use in the field of blood analysis; trace element preparations for human usedietary and nutritional supplements; clinical medical reagents; therapeutic drugs for treating cancer and drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; antigens being pharmaceutical preparations for stimulating immune responses; colostral antibodies for medical purposes
Classe 42
Research relating to sciencescientific research; multiple nucleic acid scientific analysis; molecular scientific analysis; development of biotechnology; biochemical analysis; drug discovery services; new product design services; pharmaceutical research and development; clinical research in the field of medicine; services for assessing the efficiency of pharmaceuticalsproduct quality testing; fusion protein scientific analysis; computer programming services in the medical field; medical laboratories; computer project management services relating to imaging medical data; medicine research being medical research; analysis and evaluation of medical product developmentproduct quality testing; providing scientific information on the testinginspection and research of medical products; scientific laboratory services relating to the production of bispecific antibody; drug development of bispecific antibody; scientific research and development for double antibody reagent; evaluating of clinical trial progressconducting clinical trials for others; conducting clinical trials for others
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/02/2026
FIMP
FINAL DISPOSITION PROCESSED
12/02/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/11/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/08/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
05/08/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/06/2025
PUBO
PUBLISHED FOR OPPOSITION
17/06/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/06/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/05/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
15/05/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
15/05/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
15/05/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
15/05/2025
DOCK
ASSIGNED TO EXAMINER
06/05/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/05/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/05/2025
DOCK
ASSIGNED TO EXAMINER
30/11/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
31/08/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
14/08/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
14/08/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/05/2024
NREV
NOTICE OF REVIVAL - E-MAILED
20/05/2024
PETG
PETITION TO REVIVE-GRANTED
20/05/2024
PROA
TEAS PETITION TO REVIVE RECEIVED
20/05/2024
MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
16/05/2024
ABN2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
16/05/2024
RFNP
REFUSAL PROCESSED BY IB
22/11/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/11/2023
RFRR
REFUSAL PROCESSED BY MPU
02/11/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/11/2023
CNRT
NON-FINAL ACTION WRITTEN
01/11/2023
DOCK
ASSIGNED TO EXAMINER
30/10/2023
MAFR
APPLICATION FILING RECEIPT MAILED
24/03/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/03/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
16/03/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace S-DUAL ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.